<!DOCTYPE html>
<html>
<head>
<title>Dovato, INN-dolutegravir, lamivudine;</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge">
</head>
<body>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:297pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:274pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">ANNEX I</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:297pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:175pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">SUMMARY OF PRODUCT CHARACTERISTICS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:297pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#008000"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:200pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato 50 mg/300 mg film-coated tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir and 300 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lamivudine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Film-coated tablet (tablet). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Oval, biconvex, white, film coated tablet, approximately 18.5 x 9.5 mm, debossed with &#x201c;SV 137&#x201d; on one face. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">integrase inhibitor class, or lamivudine (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato should be prescribed by physicians experienced in the management of HIV infection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adults and adolescents (above 12 years of age weighing at least 40</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">kg). </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The recommended dose of Dovato in adults and adolescents is one 50 mg/300 mg tablet once daily. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Dose adjustments </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A separate preparation of dolutegravir is available where a dose adjustment is indicated due to drug-drug </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">interactions (e.g. rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John&#x2019;s wort, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">etravirine (without boosted protease inhibitors), efavirenz, nevirapine, or tipranavir/ritonavir, see sections 4.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 4.5). In these cases the physician should refer to the individual product information for dolutegravir. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Missed doses </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If the patient misses a dose of Dovato, the patient should take Dovato as soon as possible, providing the next </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose is not due within 4 hours. If the next dose is due within 4 hours, the patient should not take the missed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose and simply resume the usual dosing schedule. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are limited data available on the use of Dovato in patients aged 65 years and over. No dose adjustment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is necessary (see section 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment </span></i></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato is not recommended for use in patients with a creatinine clearance &lt; 30 mL/min (see section 5.2). No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose adjustment is required in patients with mild or moderate renal impairment. However, the lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exposure is significantly increased in patients with a creatinine clearance &lt; 50 mL/min (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh grade A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or B). No data are available in patients with severe hepatic impairment (Child-Pugh grade C); therefore </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato should be used with caution in these patients (see section 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population</span></i><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Dovato in children aged less than 12 years or weighing less than 40 kg have not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">been established. No data are available. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Oral use.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato can be taken with or without food (see section 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Co-administration with medicinal products with narrow therapeutic windows, that are substrates of organic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cation transporter (OCT) 2, including but not limited to fampridine (also known as dalfampridine; see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity reactions have been reported with dolutegravir, and were characterized by rash, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">constitutional findings, and sometimes, organ dysfunction, including severe liver reactions. Dovato and other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">suspect medicinal products should be discontinued immediately if signs or symptoms of hypersensitivity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions develop (including, but not limited to, severe rash or rash accompanied by raised liver enzymes, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial oedema, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">eosinophilia, angioedema). Clinical status including liver aminotransferases and bilirubin should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monitored. Delay in stopping treatment with Dovato or other suspect active substances after the onset of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypersensitivity may result in a life-threatening allergic reaction.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Weight and metabolic parameters </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">changes may in part be linked to disease control and lifestyle. For lipids and weight, there is in some cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evidence for a treatment effect. For monitoring of blood lipids and glucose reference is made to established </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Liver disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">risk of severe and potentially fatal hepatic adverse reactions. In case of concomitant antiviral therapy for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis B or C, please refer also to the relevant product information for these medicinal products. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato includes lamivudine, which is active against hepatitis B. Dolutegravir lacks such activity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine monotherapy is generally not considered an adequate treatment for hepatitis B, since the risk for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis B resistance development is high. If Dovato is used in patients co-infected with hepatitis B an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">additional antiviral is therefore generally needed. Reference should be made to treatment guidelines. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If Dovato is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of both liver </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">an acute exacerbation of hepatitis.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with pre-existing liver dysfunction, including chronic active hepatitis have an increased frequency of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">liver function abnormalities during combination antiretroviral therapy, and should be monitored according to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">standard practice. If there is evidence of worsening liver disease in such patients, interruption or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">discontinuation of treatment must be considered.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immune Reactivation Syndrome </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In HIV-infected patients with severe immune deficiency at the time of institution of combination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Cytomegalovirus retinitis</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, generalised and/or focal mycobacterial infections, and </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pneumocystis jirovecii</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pneumonia (often referred to as PCP). Any inflammatory symptoms should be evaluated and treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">instituted when necessary. Autoimmune disorders (such as Graves&#x2019; disease and autoimmune hepatitis) have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">variable and these events can occur many months after initiation of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some hepatitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">B and/or C co-infected patients at the start of dolutegravir therapy. Monitoring of liver chemistries is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended in patients with hepatitis B and/or C co-infection. (See &#x2018;Liver disease&#x2019; earlier in this section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and also see section 4.8).</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mitochondrial dysfunction following exposure </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nucleoside and nucleotide analogues may impact mitochondrial function to a variable degree, which is most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dysfunction in HIV-negative infants exposed </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and/or post-natally to nucleoside analogues, these have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported are haematological disorders (anaemia, neutropenia), and metabolic disorders (hyperlactatemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperlipasemia). These reactions have often been transitory. Some late-onset neurological disorders have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">transient or permanent is currently unknown. These findings should be considered for any child exposed </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> to nucleoside and nucleotide analogues, who presents with severe clinical findings of unknown </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aetiology, particularly neurologic findings. These findings do not affect current national recommendations to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Osteonecrosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although the aetiology is considered to be multifactorial (including corticosteroid use, biphosphonates, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reported in patients with advanced HIV-disease and/or long-term exposure to CART. Patients should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">movement. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Opportunistic infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients should be advised that dolutegravir, lamivudine or any other antiretroviral therapy does not cure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV infection and that they may still develop opportunistic infections and other complications of HIV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infection. Therefore, patients should remain under close clinical observation by physicians experienced in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment of these associated HIV diseases. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Administration in subjects with moderate renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with a creatinine clearance between 30 and 49 mL/min receiving Dovato may experience a 1.6-to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3.3-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fold higher lamivudine exposure (AUC) than patients with a creatinine clearance &#x2265;50 mL/min. There are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">no safety data from randomized, controlled trials comparing Dovato to the individual components in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with a creatinine clearance between 30 and 49 mL/min who received dose-adjusted lamivudine. In the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">original lamivudine registrational trials in combination with zidovudine, higher lamivudine exposures were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">associated with higher rates of haematologic toxicities (neutropenia and anaemia), although discontinuations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">due to neutropenia or anaemia each occurred in &lt;1% of subjects. Other lamivudine-related adverse events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(such as gastro-intestinal and hepatic disorders) may occur. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients with a sustained creatinine clearance between 30 and 49 mL/min who receive Dovato should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monitored for lamivudine-related adverse events, notably haematologic toxicities. If new or worsening </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">neutropenia or anaemia develop, a dose adjustment of lamivudine, per lamivudine prescribing information, is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">indicated, which cannot be achieved with Dovato. Dovato should be discontinued and the individual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">components should be used to construct the treatment regimen. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Drug interactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The recommended dose of dolutegravir is 50 mg twice daily when co-administered with rifampicin, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John&#x2019;s wort, etravirine (without boosted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">protease inhibitors), efavirenz, nevirapine, or tipranavir/ritonavir (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato should not be co-administered with polyvalent cation-containing antacids. Polyvalent cation-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">containing antacids are recommended to be taken 2 hours after or 6 hours before Dovato (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">When taken with food, Dovato and supplements or multivitamins containing calcium, iron or magnesium can </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be taken at the same time. If Dovato is administered under fasting conditions, supplements or multivitamins </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">containing calcium, iron or magnesium are recommended to be taken 2 hours after or 6 hours before Dovato </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir increased metformin concentrations. A dose adjustment of metformin should be considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when starting and stopping coadministration of Dovato with metformin, to maintain glycaemic control (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.5). Metformin is eliminated renally and, therefore, it is of importance to monitor renal function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when co-treated with Dovato. This combination may increase the risk for lactic acidosis in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">moderate renal impairment (stage 3a creatinine clearance 45&#x2013; 59 mL/min) and a cautious approach is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended. Reduction of the metformin dose should be highly considered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The combination of Dovato with cladribine is not recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato should not be taken with any other medicinal product containing dolutegravir, lamivudine or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emtricitabine, except where a dose adjustment of dolutegravir is indicated due to drug-drug interactions (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No drug interaction studies have been conducted using Dovato. Dovato contains dolutegravir and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lamivudine, therefore any interactions identified for these individually are relevant to Dovato. No clinically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significant drug interactions are expected between dolutegravir and lamivudine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:771pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Effect of other medicinal products on the pharmacokinetics of dolutegravir and lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir is eliminated mainly through metabolism by uridine diphosphate glucuronosyl transferase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(UGT) 1A1. Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, P-glycoprotein (P-gp), and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">breast cancer resistance protein</span><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(BCRP). Co-administration of Dovato and other medicinal products that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibit UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or P-gp may, therefore, increase dolutegravir plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentration. Medicinal products that induce those enzymes or transporters may decrease dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">plasma concentration and reduce the therapeutic effect of dolutegravir. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The absorption of dolutegravir is reduced by certain metal cation-containing anti-acid substances and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supplements (see Table 1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine is cleared renally. Active renal secretion of lamivudine in the urine is mediated through the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">OCT2 and multidrug and toxin extrusion transporters (MATE1 and MATE2-K). Trimethoprim (an inhibitor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of these transporters) has been shown to increase lamivudine plasma concentrations, however the resulting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increase was not clinically significant (see Table 1). Dolutegravir is an OCT2 and MATE1 inhibitor; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">however, lamivudine concentrations were similar with or without co-administration of dolutegravir based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a cross study analysis, indicating that dolutegravir has no relevant effect on lamivudine exposure </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine is also substrate of the hepatic uptake transporter OCT1. As hepatic elimination plays a minor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">role in the clearance of lamivudine, drug interactions due to inhibition of OCT1 are unlikely to be of clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significance. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although lamivudine is a substrate of BCRP and P-gp </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, given its high absolute bioavailability, (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 5.2), inhibitors of these efflux transporters are unlikely to result in a clinically relevant impact on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lamivudine concentrations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Effect of dolutegravir and lamivudine on the pharmacokinetics of other medicinal products </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, dolutegravir did not have an effect on midazolam, a CYP3A4 probe. Based on </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and/or </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">any major enzyme or transporter such as CYP3A4, CYP2C9 and P-gp (for more information see section 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, dolutegravir inhibited the renal transporters OCT2 and MATE1. </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, a 10-14% decrease of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine clearance (secretory fraction is dependent on OCT2 and MATE1 transport) was observed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients. </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, dolutegravir may increase plasma concentrations of medicinal products in which excretion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is dependent upon OCT2 and/or MATE1 (e.g. fampridine [also known as dalfampridine], metformin) (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Table 1 and section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, dolutegravir inhibited the renal uptake organic anion transporters (OAT)1 and OAT3. Based on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lack of effect on the </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> pharmacokinetics of the OAT substrate tenofovir, </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> inhibition of OAT1 is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">unlikely. Inhibition of OAT3 has not been studied </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. Dolutegravir may increase plasma concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of medicinal products in which excretion is dependent upon OAT3. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro,</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> lamivudine was an inhibitor of OCT1 and OCT2; the clinical consequences are not known. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Established and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products are listed in Table 1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interaction table </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interactions between dolutegravir, lamivudine and co-administered medical products are listed in Table 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increase is indicated as &#x201c;&#x2191;&#x201d;, decrease as &#x201c;&#x2193;&#x201d;, no change as &#x201c;&#x2194;&#x201d;, area under the </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentration versus time </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">curve as &#x201c;AUC&#x201d;, maximum observed concentration as &#x201c;C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x201d;, concentration at end of dosing interval as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x201c;C&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x201d;). The table should not be considered exhaustive but is representative of the classes studied. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 1: </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:128pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Drug Interactions </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Medicinal products by </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">therapeutic areas</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:216pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction geometric </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:216pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">mean change (%)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:344pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Recommendations concerning co-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:344pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">administration</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Antiretroviral medicinal products</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:62pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Non-nucleoside reverse transcriptase inhibitors </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Etravirine without boosted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">protease inhibitors / </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 71% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 52% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 88% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Etravirine </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(induction of UGT1A1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and CYP3A enzymes) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Etravirine without boosted protease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitors decreased plasma dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentration. The recommended dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of dolutegravir is 50 mg twice daily for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients taking etravirine without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">boosted protease inhibitors. As Dovato </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is a fixed-dose tablet, an additional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50 mg tablet of dolutegravir should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administered, approximately 12 hours </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after Dovato for the duration of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">etravirine without boosted protease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitor co-administration (a separate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">formulation of dolutegravir is available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for this dose adjustment, see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lopinavir+ritonavir+etravirine/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 11% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 28% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lopinavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ritonavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Etravirine </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Darunavir+ritonavir+etravirine/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 25% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 12% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 36% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Darunavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ritonavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Etravirine </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Efavirenz/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 57% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 39% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 75% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Efavirenz </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (historical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">controls) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(induction of UGT1A1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and CYP3A enzymes) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The recommended dose of dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is 50 mg twice daily when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">co-administered with efavirenz. As </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato is a fixed-dose tablet, an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">additional 50 mg tablet of dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be administered, approximately </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12 hours after Dovato for the duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the efavirenz co-administration (a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">separate formulation of dolutegravir is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available for this dose adjustment, see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nevirapine/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Not studied, a similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduction in exposure as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed with efavirenz is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected, due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">induction) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The recommended dose of dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is 50 mg twice daily when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">co-administered with nevirapine. As </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato is a fixed-dose tablet, an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">additional 50 mg tablet of dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be administered, approximately </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12 hours after Dovato for the duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:762pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the nevirapine co-administration (a </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">separate formulation of dolutegravir is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available for this dose adjustment, see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rilpivirine/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 12% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 13% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C&#x3c4; </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 22% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rilpivirine </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:62pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nucleoside reverse transcriptase inhibitors (NRTIs) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tenofovir disoproxil  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Emtricitabine, didanosine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">stavudine, tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alafenamide, zidovudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tenofovir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interaction not studied </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato is combined with tenofovir, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">didanosine, stavudine or zidovudine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato is not recommended for use in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combination with emtricitabine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">containing products, since both </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lamivudine (in Dovato) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">emtricitabine are cytidine analogues (i.e. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">risk for intracellular interactions), see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:62pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Protease inhibitors </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Atazanavir/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 91% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 50% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 180% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Atazanavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (historical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">controls) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(inhibition of UGT1A1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and CYP3A enzymes) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Atazanavir+ ritonavir/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 62% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 34% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 121% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Atazanavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ritonavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tipranavir+ritonavir/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 59% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 47% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:12pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 76% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tipranavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ritonavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(induction of UGT1A1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and CYP3A enzymes) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The recommended dose of dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is 50 mg twice daily when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">co administered with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tipranavir/ritonavir. As Dovato is a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fixed-dose tablet, an additional 50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tablet of dolutegravir should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administered, approximately 12 hours </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after Dovato for the duration of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tipranavir/ritonavir co-administration (a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">separate formulation of dolutegravir is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available for this dose adjustment, see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fosamprenavir+ritonavir/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 35% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 24% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 49% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:766pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fosamprenavir</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fosamprenavir/ritonavir decreases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir concentrations, but based </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:726pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">on limited data, did not result in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:739pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decreased efficacy in Phase III studies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary.  </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:292pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ritonavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(induction of UGT1A1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and CYP3A enzymes) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lopinavir+ritonavir/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">24</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lopinavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ritonavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Darunavir+ritonavir/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 22%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 11% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 38% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Darunavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ritonavir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(induction of UGT1A1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and CYP3A enzymes) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Other antiviral active substances </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Daclatasvir/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 33%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 29% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 45% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Daclatasvir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Daclatasvir did not change dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">plasma concentration to a clinically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">relevant extent. Dolutegravir did not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">change daclatasvir plasma concentration. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ledipasvir/Sofosbuvir/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine (with abacavir) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ledipasvir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sofosbuvir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sofosbuvir/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Velpatasvir/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sofosbuvir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Velpatasvir</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ribavirin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interaction not studied. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinically significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">interaction unlikely. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Anti-infective products</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Trimethoprim/sulfamethoxazole </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Co-trimoxazole)/Lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(160 mg/800 mg once daily for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 days/300 mg single dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 43% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Trimethoprim:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sulfamethoxazole:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(organic cation transporter </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibition) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Antimycobacterials</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rifampicin/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 54% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 43% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 72% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The recommended dose of dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is 50 mg twice daily when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">co-administered with rifampicin. As </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:750pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato is a fixed-dose tablet, an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:762pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">additional 50 mg tablet of dolutegravir </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(induction of UGT1A1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and CYP3A enzymes) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be administered, approximately </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12 hours after Dovato for the duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the rifampicin co-administration (a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">separate formulation of dolutegravir is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available for this dose adjustment, see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rifabutin/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 16% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C&#x3c4; </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 30% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(induction of UGT1A1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and CYP3A enzymes) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Anticonvulsants</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Carbamazepine/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 49% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 33% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x3c4;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 73% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The recommended dose of dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is 50 mg twice daily when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">co-administered with these metabolic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inducers. As Dovato is a fixed-dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tablet, an additional 50 mg tablet of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir should be administered, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately 12 hours after Dovato for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the duration of the co-administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with these metabolic inducers (a separate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">formulation of dolutegravir is available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for this dose adjustment, see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Phenobarbital/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Phenytoin/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Oxcarbazepine/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Not studied, decrease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected due to induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of UGT1A1 and CYP3A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">enzymes, a similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduction in exposure as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">carbamazepine is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Antihistamines (histamine H2 receptor antagonists)</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ranitidine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interaction not studied. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinically significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">interaction unlikely. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cimetidine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interaction not studied. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinically significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">interaction unlikely. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Cytotoxics</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cladribine/Lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interaction not studied.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:216pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibits the intracellular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">phosphorylation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cladribine leading to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">potential risk of cladribine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">loss of efficacy in case of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combination in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical setting. Some </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical findings also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">support a possible </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">interaction between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lamivudine and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cladribine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concomitant use of Dovato with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cladribine is not recommended (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Miscellaneous</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:62pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Sorbitol </span></i></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">11 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sorbitol solution (3.2</span><span style="font-family:ArialNarrow,sans-serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">g, 10.2</span><span style="font-family:ArialNarrow,sans-serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">g, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">13.4</span><span style="font-family:ArialNarrow,sans-serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">g)/Lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Single dose lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oral solution 300 mg.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:89pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 14%; 32%; 36%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 28%; 52%, 55%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">When possible, avoid chronic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">coadministration of Dovato with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medicinal products containing sorbitol </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or other osmotic acting poly-alcohols or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monosaccharide alcohols (eg: xylitol, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mannitol, lactitol, maltitol). Consider </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">more frequent monitoring of HIV-1 viral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">load when chronic coadministration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cannot be avoided. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:62pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Potassium channel blockers</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fampridine (also known as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dalfampridine)/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fampridine </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Co-administration of dolutegravir has </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the potential to cause seizures due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased fampridine plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentration via inhibition of OCT2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">transporter; co-administration has not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">been studied. Fampridine co-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration with Dovato is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraindicated (see section 4.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:62pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Antacids and supplements </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aluminium-containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antacids/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 74%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 72% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Complex binding to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">polyvalent ions) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium/ aluminium-containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antacids should be taken well separated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in time from the administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato (minimum 2 hours after or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 hours before). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Calcium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supplements/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(fasted intake) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 39%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 37% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">24</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 39% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Complex binding to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">polyvalent ions) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">- When taken with food, Dovato and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supplements or multivitamins containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">calcium, iron or magnesium can be taken </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at the same time.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">- If Dovato is taken in a fasted state, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">such supplements should be taken a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">minimum 2 hours after or 6 hours before </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the intake of Dovato. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The stated reductions in dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exposure were observed with the intake </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of dolutegravir and these supplements </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">during fasted conditions. In fed state, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">changes in exposure following intake </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">together with calcium or iron </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supplements were modified by the food </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect, resulting in an exposure similar to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that obtained with dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administered in the fasted state. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Iron supplements/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(fasted intake) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 54%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 57% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">24</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 56% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Complex binding to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">polyvalent ions) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Multivitamins (containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">calcium, iron and magnesium) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(fasted intake) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 33%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 35% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">24</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 32% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Complex binding to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">polyvalent ions) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:62pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Proton pump inhibitors </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Omeprazole </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:62pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Corticosteroids </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Prednisone/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 11% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:216pt"><span style="font-family:ArialNarrow,sans-serif;font-size:12pt">   </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt">C&#x3c4; </span><span style="font-family:SymbolMT,sans-serif;font-size:12pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> 17%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:62pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Antidiabetics </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metformin/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:741pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metformin </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A dose adjustment of metformin should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be considered when starting and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">stopping coadministration of Dovato </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">When co-administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with dolutegravir 50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">QD: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metformin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 79%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 66% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">When co-administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with dolutegravir 50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">BID:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   Metformin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 145 %  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 111% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with metformin, to maintain glycaemic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">control. In patients with moderate renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impairment a dose adjustment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metformin should be considered when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">coadministered with Dovato, because of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the increased risk for lactic acidosis in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with moderate renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">due to increased metformin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentration (section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:62pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Herbal products </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">St. John&#x2019;s wort/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Not studied, decrease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected due to induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of UGT1A1 and CYP3A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">enzymes, a similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduction in exposure as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">carbamazepine is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The recommended dose of dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is 50 mg twice daily when co-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administered with St. John&#x2019;s wort. As </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato is a fixed-dose tablet, an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">additional 50 mg tablet of dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be administered, approximately </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12 hours after Dovato for the duration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the St. John&#x2019;s wort co-administration (a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">separate formulation of dolutegravir is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available for this dose adjustment, see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:62pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Oral contraceptives </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ethinyl estradiol (EE) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Norgestromin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(NGMN)/Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Effect of dolutegravir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EE </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2191;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 3%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Effect of dolutegravir: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">NGMN </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2194;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   AUC </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 2%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:216pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">   C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2193;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 11% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir had no pharmacodynamic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect on Luteinizing Hormone (LH), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Follicle Stimulating Hormone (FSH) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">progesterone. No dose adjustment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oral contraceptives is necessary when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:344pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">co-administered with Dovato. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Interaction studies have only been performed in adults. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Women of childbearing potential </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Women of childbearing potential (WOCBP) should be counselled about the potential risk of neural tube </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">defects with dolutegravir (a component of Dovato, see below), including consideration of effective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraceptive measures. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If a woman plans pregnancy, the benefits and the risks of continuing treatment with Dovato should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">discussed with the patient. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of a dual regimen has not been studied in pregnancy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">13 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Human experience from a birth outcome surveillance study in Botswana shows a small increase of neural </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tube defects; 7 cases in 3,591 deliveries (0.19%; 95% CI 0.09%, 0.40%) to mothers taking dolutegravir-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">containing regimens at the time of conception compared to 21 cases in 19,361 deliveries (0.11%: 95% CI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.07%, 0.17%) to women exposed to non-dolutegravir regimens at the time of conception. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(0.05-0.1%). Most neural tube defects occur within the first 4 weeks of embryonic development after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">conception (approximately 6 weeks after the last menstrual period). If a pregnancy is confirmed in the first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trimester while on Dovato, the benefits and risks of continuing Dovato versus switching to another </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antiretroviral regimen should be discussed with the patient taking the gestational age and the critical time </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">period of neural tube defect development into account. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data analysed from the Antiretroviral Pregnancy Registry do not indicate an increased risk of major birth </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">defects in over 600 women exposed to dolutegravir during pregnancy but are currently insufficient to address </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the risk of neural tube defects.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In animal reproductive toxicology studies with dolutegravir, no adverse development outcomes, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">neural tube defects, were identified (see section 5.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">More than 1000 outcomes from exposure to dolutegravir during second and third trimester pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">indicate no evidence of increased risk of foetal/neonatal toxicity. Dovato may be used during the second and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">third trimester of pregnancy when the expected benefit justifies the potential risk to the foetus. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir crosses the placenta in humans. In pregnant women living with HIV, the median foetal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">umbilical cord concentration of dolutegravir was approximately 1.3-fold greater compared with the maternal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">peripheral plasma concentration. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is insufficient information on the effects of dolutegravir on neonates. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A large amount of data on the use of lamivudine in pregnant women (more than 5200 outcomes from first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trimester) indicates no malformative toxicity.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Animal studies showed lamivudine may inhibit cellular DNA replication (see section 5.3). The clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">relevance of these findings is unknown. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Mitochondrial dysfunction</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nucleoside and nucleotide analogues have been demonstrated </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> to cause a variable degree </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of mitochondrial damage. There have been reports of mitochondrial dysfunction in HIV-negative infants </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exposed </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in utero</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and/or post-natally to nucleoside analogues (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir is excreted in human milk in small amounts (a median dolutegravir breast milk to maternal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">plasma ratio of 0.033 has been shown). There is insufficient information on the effects of dolutegravir in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">neonates/infants.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">infants of mothers treated for HIV are very low (&lt; 4% of maternal serum concentrations) and progressively </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decrease to undetectable levels when breastfed infants reach 24 weeks of age. There are no data available on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the safety of lamivudine when administered to babies less than three months old. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is recommended that women living with HIV do not breast-feed their infants in order to avoid transmission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of HIV. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility  </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">14 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are no data on the effects of dolutegravir or lamivudine on human male or female fertility. Animal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies indicate no effects of dolutegravir or lamivudine on male or female fertility (see section 5.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato has no or negligible influence on the ability to drive and use machines. Patients should be informed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that dizziness and somnolence has been reported during treatment with dolutegravir. The clinical status of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the patient and the adverse reaction profile of Dovato should be borne in mind when considering the patient&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ability to drive or operate machinery.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Summary of the safety profile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The most frequently reported adverse reactions are headache (3%), diarrhoea (2%), nausea (2%) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">insomnia (2%).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The most severe adverse reaction reported with dolutegravir was a hypersensitivity reaction that included </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rash and severe liver effects (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tabulated list of adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The adverse reactions from clinical study and post-marketing experience are listed in Table 2 by body </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">system, organ class and absolute frequency. Frequencies are defined as very common (</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10), common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/100 to &lt;1/10), uncommon (</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/1,000 to &lt;1/100), rare (</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">known (cannot be estimated from the available data). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 2: </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:128pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Tabulated summary of adverse reactions to Dovato based on clinical study and post-</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:128pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">marketing experience with Dovato and its individual components  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:102pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Frequency </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:221pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adverse reaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:102pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Blood and lymphatic systems disorders: </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">neutropenia, anaemia, thrombocytopenia</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pure red cell aplasia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:102pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immune system disorders: </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:547pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:547pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypersensitivity (see section 4.4), immune reconstitution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">syndrome (see section 4.4)</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:102pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metabolism and nutrition disorders: </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lactic acidosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:102pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Psychiatric disorders:  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">depression, anxiety, insomnia, abnormal dreams </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">suicidal ideation*, suicide attempt*, panic attack </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">*particularly in patients with a pre-existing history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">depression or psychiatric illness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">completed suicide* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">*particularly in patients with a pre-existing history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:762pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">depression or psychiatric illness. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">15 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:60pt;left:102pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nervous system disorders:  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:80pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">headache</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness, somnolence</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">peripheral neuropathy, paraesthesia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:102pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Gastrointestinal disorders:  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nausea, diarrhoea</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vomiting, flatulence, abdominal pain/ discomfort</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pancreatitis</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:102pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatobiliary disorders: </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alanine aminotransferase (ALT) and/or aspartate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aminotransferase (AST) elevations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">acute hepatic failure</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, increased bilirubin</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:102pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Skin and subcutaneous tissue disorders:  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rash, pruritus, alopecia</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angioedema </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:102pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Musculoskeletal and connective tissue disorders: </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthralgia, muscle disorders (including myalgia)</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rhabdomyolysis</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:102pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">General disorders and administration site conditions:  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fatigue</span><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:102pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Investigations: </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatine phosphokinase (CPK) elevations, weight increased</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:221pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">amylase elevations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> This adverse reaction was identified through post-marketing surveillance for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir in combination with other ARVs. The frequency category of rare was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">estimated based on post-marketing reports. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:102pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> In combination with increased transaminases. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Description of selected adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Changes in laboratory biochemistries </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir has been associated with an increase in serum creatinine occuring in the first week of treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when administered with other antiretroviral medicinal products. Increases in serum creatinine occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">within the first four weeks of treatment with dolutegravir plus lamivudine and remained stable through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">48 weeks. In the pooled GEMINI studies a mean change from baseline of 10.3 &#xb5;mol/L (range: -36.3 &#xb5;mol/L </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to 55.7 &#xb5;mol/L) was observed after 48 weeks of treatment. These changes are linked to the inhibiting effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of dolutegravir on renal tubular transporters of creatinine. The changes are not considered to be clinically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">relevant and do not reflect a change in glomerular filtration rate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Co-infection with Hepatitis B or C </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the Phase III studies for the dolutegravir single agent, patients with hepatitis B and/or C co-infection were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:762pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">16 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">normal (ULN). Overall, the safety profile in patients co-infected with hepatitis B and/or C was similar to that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed in patients without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were higher in the subgroup with hepatitis B and/or C co-infection for all treatment groups. Liver chemistry </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">elevations consistent with immune reconstitution syndrome were observed in some subjects with hepatitis B </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and/or C co-infection at the start of dolutegravir therapy, particularly in those whose anti-hepatitis B therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was withdrawn (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Metabolic parameters  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Osteonecrosis  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">advanced HIV disease or long-term exposure to CART. The frequency of this is unknown (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Immune response syndrome </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Autoimmune disorders (such as Graves&#x2019; disease and autoimmune hepatitis) have also been reported; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">however, the reported time to onset is more variable and these events can occur many months after initiation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of treatment (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are no clinical study data on the effects of Dovato in the paediatric population. Individual components </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been investigated in adolescents (12 to 17 years). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on limited available data with the dolutegravir single entity or lamivudine single entity used in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combination with other antiretroviral agents to treat adolescents (12 to 17 years), there were no additional </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">types of adverse reactions beyond those observed in the adult population. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to report any suspected adverse reactions via the national reporting system listed in </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">Appendix V</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No specific symptoms or signs have been identified following acute overdose with dolutegravir or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lamivudine, apart from those listed as adverse reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no specific treatment for an overdose of Dovato. If overdose occurs, the patient should be treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supportively with appropriate monitoring, as necessary. Since lamivudine is dialysable, continuous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">haemodialysis could be used in the treatment of overdose, although this has not been studied. As dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: Antivirals for systemic use, antivirals for treatment of HIV infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combinations. ATC code: J05AR25 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">17 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine, via its active metabolite 5&apos;-triphosphates (TP) (an analogue for cytidine), inhibits reverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">transcriptase of HIV-1 and HIV-2 through incorporation of the monophosphate form into the viral DNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chain, resulting in chain termination. Lamivudine triphosphate shows significantly less affinity for host cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">DNA polymerases. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacodynamic effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Antiviral activity in cell culture  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir and lamivudine have been shown to inhibit replication of lab-strains and clinical isolates of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV in a number of cell types, including transformed T cell lines, monocyte/macrophage derived lines and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">primary cultures of activated peripheral blood mononuclear cells (PMBCs) and monocyte/macrophages. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentration of active substance necessary to effect viral replication by 50% (IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> - half maximal inhibitory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentration) varied according to virus and host cell type. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> for dolutegravir in various lab-strains using PBMC was 0.5 nM, and when using MT-4 cells it </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ranged from 0.7-2 nM. Similar IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">s were seen for clinical isolates without any major difference between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subtypes; in a panel of 24 HIV-1 isolates of clades A, B, C, D, E, F and G and group O the mean IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was 0.2 nM (range 0.02-2.14). The mean IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> for 3 HIV-2 isolates was 0.18 nM (range 0.09-0.61). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The median or mean IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values for lamivudine against lab-strains of HIV-1 ranged from 0.007 to 2.3 </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb5;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">M. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The mean IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> against lab-strains of HIV-2 (LAV2 and EHO) ranged from 0.16 to 0.51 </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb5;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">M for lamivudine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values of lamivudine against HIV-1 subtypes (A-G) ranged from 0.001 to 0.170 </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb5;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">M, against Group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">O from 0.030 to 0.160 </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb5;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">M and against HIV-2 isolates from 0.002 to 0.120 </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb5;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">M in peripheral blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mononuclear cells. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV-1 isolates (CRF01_AE, n=12; CRF02_AG, n=12; and Subtype C or CRF_AC, n=13) from 37 untreated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients in Africa and Asia were susceptible to lamivudine (IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> fold changes &lt; 3.0). Group O isolates from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antiviral na&#xef;ve patients tested for lamivudine activity were highly sensitive. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effect of human serum  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In 100% human serum, the mean fold shift for dolutegravir activity was 75 fold, resulting in protein adjusted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">90</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of 0.064 </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb5;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">g/mL. Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">displays low plasma protein binding (less than 36%).</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Resistance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato is indicated in the absence of documented or suspected resistance to the integrase inhibitor class and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to lamivudine (see section 4.1). For information around in vitro resistance, and cross resistance to other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">agents of the integrase- and NRTI class, please refer to the SmPCs of dolutegravir and lamivudine.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">None of the twelve subjects in the dolutegravir plus lamivudine group or the nine subjects in the dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">plus tenofovir disoproxil/emtricitabine FDC group that met virological withdrawal criteria through Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">144 across the GEMINI-1 (204861) and GEMINI-2 (205543) studies had treatment emergent integrase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitor or NRTI class resistance. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In previously untreated patients receiving dolutegravir + 2 NRTIs in Phase IIb and Phase III, no development </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of resistance to the integrase inhibitor class, or to the NRTI class was seen (n=1118 follow-up of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">48-96 weeks).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Effects on electrocardiogram </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No relevant effects were seen with dolutegravir on the QTc interval, with doses exceeding the clinical dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">by approximately three fold. A similar study was not conducted with lamivudine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical efficacy and safety</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Antiretroviral na&#xef;ve subjects</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of Dovato is supported by data from 2 identical 148-week, Phase III, randomised, double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">multicentre, parallel-group, non-inferiority controlled trials GEMINI-1 (204861) and GEMINI-2 (205543). A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">total of 1433 HIV-1 infected antiretroviral treatment-na&#xef;ve adult subjects received treatment in the trials. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subjects were enrolled with a screening plasma HIV-1 RNA of 1000 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">c/mL to &#x2264;500,000</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> c/mL. Subjects were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">randomised to a two-drug regimen of dolutegravir 50 mg plus lamivudine 300 mg once daily or dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50 mg plus tenofovir disoproxil/emtricitabine 245/200 mg once daily. The primary efficacy endpoint for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">each GEMINI trial was the proportion of subjects with plasma HIV-1 RNA &lt;50 copies/mL at Week 48 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Snapshot algorithm for the ITT-E population). Double blind therapy  continued up to week 96, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">open label therapy up to week 148. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At baseline, in the pooled analysis, the median age of subjects was 33 years, 15% were female, 69% were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">white, 9% were CDC Stage 3 (AIDS), 20% had HIV-1 RNA &gt;100,000 copies/mL, and 8% had CD4+ cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">count less than 200 cells per mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">; these characteristics were similar between studies and treatment arms.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the primary week 48 analysis, dolutegravir plus lamivudine was non-inferior to dolutegravir plus tenofovir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disoproxil/emtricitabine FDC in GEMINI-1 and GEMINI-2 studies. This was supported by the pooled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">analysis, see Table 3. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">19 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:128pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Virologic Outcomes of Randomised Treatment of GEMINI at Week 48 (Snapshot </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:128pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">algorithm) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:314pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">GEMINI-1 and GEMINI-2 Pooled </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:381pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Data</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">*</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:319pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DTG + 3TC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:332pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">N=716 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:401pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DTG + TDF/FTC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:427pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">N=717 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">HIV-1 RNA &lt;50 copies/mL</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">91% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:432pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">93% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> Treatment Difference</span></b><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x2020; </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(95%</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">confidence intervals)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:363pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.7 (-4.4, 1.1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Virologic non response</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:435pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reasons</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:442pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data in window and &#x2265;50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> copies/mL  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:432pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued for lack of efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:432pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued for other reasons and &#x2265;50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> copies/mL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:432pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Change in ART </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:432pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">No virologic data at Week 48 window </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:435pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reasons</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:442pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:71pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued study due to adverse event or death  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:435pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:71pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued study for other reasons </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:435pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:71pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Missing data during window but on study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:435pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:251pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">HIV-1 RNA &lt;50 copies/mL by baseline covariates</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:330pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">n/N (%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:424pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">n/N (%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Baseline Plasma Viral Load (copies/mL) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;100,000</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&gt;100,000 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:312pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">526 / 576 (91%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:312pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">129 / 140 (92%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:442pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:406pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">531 / 564 (94%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:406pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">138 / 153 (90%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Baseline CD4+ (cells/ mm</span></b><sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:6.96pt">3</span></b></sup><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:442pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;200</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:317pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50 / 63 (79%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:412pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">51 / 55 (93%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> &gt;200 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:312pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">605 / 653 (93%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:406pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">618 / 662 (93%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">HIV-1 subtype </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:442pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> B </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:312pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">424 / 467 (91%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:406pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">452 / 488 (93%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:317pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">84 / 86 (98%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:412pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">74 / 78 (95%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> Other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:312pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">147 / 163 (90%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:406pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">143 / 151 (95%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Gender </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:400pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> Male </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:312pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">555 / 603 (92%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:406pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">580 / 619 (94%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> Female </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:312pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">100 / 113 (88%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:412pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">89 / 98 (91%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Race  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:442pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> White </span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:312pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">451 / 484 (93%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:406pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">473 / 499 (95%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> African-American/African Heritage/Other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:312pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">204 / 232 (88%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:406pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">196 / 218 (90%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">* The results of the pooled analysis are in line with those of the individual studies, for which the primary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">endpoint (difference in proportion &lt;50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">copies/mL plasma HIV-1 RNA at Week 48 based on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Snapshot algorithm for dolutegravir plus lamivudine versus dolutegravir plus tenofovir</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">disoproxil </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">/emtricitabine FDC) was met. The adjusted difference was -2.6 (95% CI: -6.7; 1.5) for GEMINI-1 and -</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.7 (95% CI: -4.3; 2.9) for GEMINI-2 with a prespecified non-inferiority margin of 10%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2020; Based on CMH-stratified analysis adjusting for the following baseline stratification factors: Plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">HIV-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1 RNA (&#x2264;100,000</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> c/mL vs. &gt;100,000 c/mL) and CD4+ cell count </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(&#x2264;200</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> vs. &gt;200 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">). Pooled analysis also stratified by study. Assessed using a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">non-inferiority margin of 10%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N = Number of subjects in each treatment group</span><span style="font-family:ArialNarrow,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At 96 weeks and at 144 weeks in the GEMINI studies, the lower bound of the 95% confidence interval for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the adjusted treatment difference of proportion of subjects with HIV-1 RNA &lt;50 copies/mL (Snapshot) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">greater than the non-inferiority margin of -10%, for the individual studies as well as pooled analysis, see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Table 4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 4</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:128pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Virologic Outcomes of Randomised Treatment of GEMINI at Weeks 96 and 144 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:128pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">(Snapshot algorithm) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:286pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">GEMINI-1 and GEMINI-2 Pooled Data</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">*</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:275pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DTG + </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:281pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3TC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:276pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">N=716 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:336pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DTG + </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:329pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">TDF/FTC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:337pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">N=717 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:396pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DTG + </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:402pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3TC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:397pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">N=716 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:456pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DTG + </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:449pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">TDF/FTC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:457pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">N=717 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:302pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 96 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:420pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Week 144 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">HIV-1 RNA &lt;50 copies/mL</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:282pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">86% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">90% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">82% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">84% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> Treatment Difference</span></b><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x2020;  </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(95%</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">confidence intervals)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:285pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-3.4% (-6.7, 0.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:406pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-1.8% (-5.8; 2.1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Virologic non response</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:285pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:345pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:405pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:465pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reasons</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:352pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:412pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:473pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data in window, &#x2265;50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> cps/mL  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:281pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:462pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued, lack of efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:285pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:405pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:462pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued, other </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reasons, &#x2265;50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> cps/mL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:281pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:465pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Change in ART </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:281pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:462pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">No virologic data at Week 96/Week 144 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">window </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reasons</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued study due to AE or death  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued study for other reasons </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:82pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Loss to follow-up </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:82pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Withdrew consent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:82pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Protocol deviations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:82pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Physicians decision </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Missing data in window, on study</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:282pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">11% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:292pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:285pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:285pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:285pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:285pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:285pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:285pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:285pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:345pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:352pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:352pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:345pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:345pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:345pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:345pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:345pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:342pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">15% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:412pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:412pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:405pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">11% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:405pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:405pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:405pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:405pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:463pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">14% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:473pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:473pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:465pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:465pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:465pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:465pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:465pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:465pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:462pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">*</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">The results of the pooled analysis are in line with those of the individual studies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2020; Based on CMH-stratified analysis adjusting for the following baseline stratification factors: Plasma HIV-1 RNA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">(&#x2264;100,000</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> c/mL vs. &gt;100,000 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">c/mL) and CD4+ cell count (&#x2264;200</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> vs. &gt;200 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">). Pooled analysis also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">stratified by study. Assessed using a non-inferiority margin of 10%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N = Number of subjects in each treatment group</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The mean increase in CD4+ T-cell counts through week 144 was 302 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in the dolutegravir plus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lamivudine arm and 300 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in the dolutegravir plus tenofovir/emtricitabine arm.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Virologically suppressed subjects</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of dolutegravir/lamivudine in virologically suppressed subjects is supported by data from a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">randomised, open-label, trial (TANGO [204862]). A total of 741 adult HIV-1 infected subjects, without any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evidence of resistance to the NRTI or integrase inhibitor (INSTI) class and who were on a stable suppressive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tenofovir alafenamide based regimen (TBR) received treatment in the studies. Subjects were randomised in a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1:1 ratio to receive dolutegravir/lamivudine FDC or continue with TBR for up to 200 weeks. Randomisation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was stratified by baseline core agent class (protease inhibitor [PI], INSTI, or non-nucleoside reverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">transcriptase inhibitor [NNRTI]). The primary efficacy endpoint was the proportion of subjects with plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 RNA &#x2265;50 c/mL (virologic non</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-response) as per the FDA Snapshot category at Week 48 (adjusted for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">randomisation stratification factor). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At baseline the median age of subjects was 39 years, 8% were female and 21% non-white, 5% were CDC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Class C (AIDS) and 98% subjects had Baseline CD4+ cell count &#x2265;200 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">; these characteristics were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">similar between treatment arms. Subjects had been on ART for a median of around 3 years prior to Day 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Around 80% were on INSTI-based TBR (mainly elvitegravir/c) at baseline. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In the primary 48 week analysis, dolutegravir/lamivudine was non-inferior to TBR, with &lt;1% of subjects in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">both arms experiencing virologic failure (HIV-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 RNA &#x2265;50 c/mL) (Table </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:762pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">21 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Table 5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:128pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Virologic Outcomes of Randomised Treatment of TANGO at Week 48 (Snapshot </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:128pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">algorithm) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:324pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DTG/3TC </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:332pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">N=369 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:431pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">TBR </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:427pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">N=372 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">HIV-1 RNA &lt;50 copies/mL*</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">93% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:432pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">93% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Virologic non response </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(</span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50 copies/mL)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">** </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:432pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Treatment Difference</span></b><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">&#x2020; </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(95%</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">confidence intervals)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:363pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">-0.3 (-1.2, 0.7) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reasons for virologic non response:</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:150pt;left:442pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data in window and &#x2265;50 copies/mL </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:435pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued for lack of efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:432pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued for other reasons and &#x2265;50 copies/mL</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:435pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:69pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Change in ART </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:435pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:62pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">No virologic data at Week 48 window </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:435pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reasons</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:348pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:442pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:71pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued study due to adverse event or death  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:432pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:71pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Discontinued study for other reasons </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:435pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6%  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:71pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Missing data during window but on study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:340pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:432pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:62pt"><span style="font-family:ArialNarrow,sans-serif;font-size:9.96pt">*</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Based on an 8% non-inferiority margin, DTG/3TC is non-inferior to TBR at Week 48 in the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">analysis (proportion of subjects achieving &lt;50 copies/mL plasma HIV-1 RNA). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">**Based on a 4% non-inferiority margin, DTG/3TC is non-inferior to TBR at Week 48 in the primary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">analysis (proportion of subjects with plasma HIV-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">1 RNA &#x2265;50 c/mL)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&#x2020;Based on CMH-stratified analysis adjusting for Baseline third agent class (PI, NNRTI, INSTI).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:62pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">N = Number of subjects in each treatment group; TBR = tenofovir alafenamide based regimen.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:62pt"><span style="font-family:ArialNarrow,sans-serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Treatment outcomes between treatment arms at week 48 were similar across the stratification factor, baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">third agent class and across subgroups by age, sex, race, baseline CD4+ cell count, CDC HIV disease stage, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and countries. The median change from baseline in CD4+ count at Week 48 was 22.5 cells per mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects who switched to dolutegravir/lamivudine and 11.0 cells per mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in subjects who stayed on TBR.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At 96 weeks in the TANGO study, the proportion of subjects with HIV-1 RNA </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50 c/mL (Snapshot) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0.3% and 1.1% in the dolutegravir/lamivudine and TBR groups, respectively. Based on a non-inferiority </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">margin of 4%, dolutegravir/lamivudine remained non-inferior to TBR, as the upper bound of the 95% CI for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the adjusted treatment difference (-2.0%; 0.4%) was less than 4% for the ITT E Population.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The median change from baseline in CD4+ T-cell counts at week 96 was 61 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3 </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir/lamivudine arm and 45 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in the TBR arm. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At 144 weeks, the proportion of subjects with HIV-1 RNA </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50 c/mL (Snapshot) was 0.3% and 1.3% in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir/lamivudine and TBR groups, respectively. Based on a non-inferiority margin of 4%, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir/lamivudine remained non-inferior to TBR, as the upper bound of the 95% CI for the adjusted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment difference (-2.4%, 0.2%) was less than 4% for the ITT E Population.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The median change from baseline in CD4+ T-cell counts at Week 144 was 36 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3 </span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir/lamivudine arm and 35 cells/mm</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">3</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> in the TBR arm. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of Dovato, or the dual combination of dolutegravir plus lamivudine (as single entities) has not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">been studied in children or adolescents. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The European Medicines Agency has deferred the obligation to submit the results of studies with Dovato in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">one or more subsets of the paediatric population in the treatment of HIV infection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:762pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">22 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">When administered in fasted state, bioequivalence regarding C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was achieved for dolutegravir, when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">comparing Dovato to dolutegravir 50 mg co-administered with lamivudine 300 mg. Dolutegravir AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">0-t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">16% higher for Dovato than for dolutegravir 50 mg co-administered with lamivudine 300 mg. This increase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not considered clinically relevant. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">When administered in fasted state, bioequivalence was achieved for lamivudine AUC, when comparing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dovato to lamivudine 300 mg co-administered with dolutegravir 50 mg. Lamivudine C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> for Dovato was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">32% higher than lamivudine 300 mg co-administered with dolutegravir 50 mg. The higher lamivudine C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not considered clinically relevant. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absorption  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir and lamivudine are rapidly absorbed following oral administration. The absolute bioavailability </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of dolutegravir has not been established. The absolute bioavailability of oral lamivudine in adults is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately 80-85%. For Dovato, the median time to maximal plasma concentration (t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) is 2.5 hours for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir and 1.0 hour for lamivudine, when dosed under fasted conditions.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Exposure to dolutegravir was generally similar between healthy subjects and HIV-1&#x2013;infected subjects. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">HIV-1&#x2013;infected adult subjects following dolutegravir 50 mg once daily, the steady-state pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">parameters (geometric mean [%CV]) based on population pharmacokinetic analyses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">(0-24)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 53.6 (27) </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb5;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">g.h/mL, C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 3.67 (20) </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb5;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">g/mL, and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">min</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> = 1.11 (46) </span><span style="font-family:SymbolMT,sans-serif;font-size:11.04pt">&#xb5;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">g/mL. Following multiple-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose oral administration of lamivudine 300 mg once daily for seven days, the mean (CV) steady-state C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.04 &#xb5;g/mL (26%) and the mean (CV) AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">(0-24)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> is 8.87 &#xb5;g.h/mL (21%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Administration of a single Dovato tablet with a high fat meal increased dolutegravir AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">(0-</span><span style="font-family:SymbolMT,sans-serif;font-size:6.96pt">&#x221e;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">33% and 21%, respectively, and decreased the lamivudine C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> by 30% compared to fasted conditions. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lamivudine AUC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">(0-</span><span style="font-family:SymbolMT,sans-serif;font-size:6.96pt">&#x221e;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was not affected by a high fat meal. These changes are not clinically significant. Dovato </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may be administered with or without food. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Distribution  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The apparent volume of distribution of dolutegravir (Vd/F) is 17-20 L. Intravenous studies with lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">showed that the mean apparent volume of distribution is 1.3 L/kg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir is highly bound (&gt; 99%) to human plasma proteins based on </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> data. Binding of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir to plasma proteins is independent of dolutegravir concentration. Total blood and plasma drug-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">related radioactivity concentration ratios averaged between 0.441 to 0.535, indicating minimal association of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">radioactivity with blood cellular components. The unbound fraction of dolutegravir in plasma is increased at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">low levels of serum albumin (&lt;35 g/L) as seen in subjects with moderate hepatic impairment. Lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exhibits linear pharmacokinetics over the therapeutic dose range and displays limited plasma protein binding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (&lt; 16%- 36% to serum albumin). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir and lamivudine are present in cerebrospinal fluid (CSF). In 13 treatment-na&#xef;ve subjects on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">stable dolutegravir plus abacavir/lamivudine regimen, dolutegravir concentration in CSF averaged 18 ng/mL </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(comparable to unbound plasma concentration, and above the IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">).</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#30849b"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The mean ratio of CSF/serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lamivudine concentrations 2-4 hours after oral administration was approximately 12%. The true extent of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CNS penetration of lamivudine and its relationship with any clinical efficacy is unknown. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir is present in the female and male genital tract. AUC in cervicovaginal fluid, cervical tissue and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vaginal tissue were 6-10% of those in corresponding plasma at steady state. AUC in semen was 7% and 17% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in rectal tissue of those in corresponding plasma at steady state. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biotransformation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir is primarily metabolized via UGT1A1 with a minor CYP3A component (9.7% of total dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administered in a human mass balance study). Dolutegravir is the predominant circulating compound in </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">23 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">plasma; renal elimination of unchanged active substance is low (&lt; 1% of the dose). Fifty-three percent of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">total oral dose is excreted unchanged in the faeces. It is unknown if all or part of this is due to unabsorbed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">active substance or biliary excretion of the glucuronidate conjugate, which can be further degraded to form </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the parent compound in the gut lumen. Thirty-two percent of the total oral dose is excreted in the urine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">represented by ether glucuronide of dolutegravir (18.9% of total dose), N-dealkylation metabolite (3.6% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">total dose), and a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism of lamivudine is a minor route of elimination. Lamivudine is predominately cleared by renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">excretion of unchanged lamivudine. The likelihood of metabolic drug interactions with lamivudine is low </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">due to the small extent of hepatic metabolism (5-10%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Drug interactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, dolutegravir demonstrated no direct, or weak inhibition (IC</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&gt;50 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x3bc;M) of the enzymes cytochrome </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">P</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">450</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 CYP3A, UGT1A1 or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">UGT2B7, or the transporters Pgp, BCRP, BSEP, organic anion transporting polypeptide (OATP) 1B1, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">OATP1B3, OCT1, MATE2-K, multidrug resistance-associated protein (MRP) 2 or MRP4. </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir did not induce CYP1A2, CYP2B6 or CYP3A4. Based on this data, dolutegravir is not expected </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to affect the pharmacokinetics of medicinal products that are substrates of major enzymes or transporters (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, dolutegravir was not a substrate of human OATP 1B1, OATP 1B3 or OCT 1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro,</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> lamivudine did not inhibit or induce CYP enzymes (such as CYP3A4, CYP2C9 or CYP2D6) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">demonstrated no or weak inhibition of OATP1B1, OAT1B3, OCT3, BCRP, P-gp, MATE1 or MATE2-K. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine is therefore not expected to affect the plasma concentrations of medicinal products that are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">substrates of these enzymes or transporters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine was not significantly metabolised by CYP enzymes. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elimination  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir has a terminal half-life of ~14 hours. The apparent oral clearance (CL/F) is approximately </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 L/hr in HIV-infected patients based on a population pharmacokinetic analysis.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The observed lamivudine half-life of elimination is 18 to 19 hours. For patients receiving lamivudine 300 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">once daily, the terminal intracellular half-life of lamivudine-TP was 16 to 19 hours. The mean systemic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clearance of lamivudine is approximately 0.32 L/h/kg, predominantly by renal clearance (&gt; 70%) via the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">organic cationic transport system. Studies in patients with renal impairment show lamivudine elimination is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">affected by renal dysfunction. Dose reduction is required for patients with creatinine clearance &lt; 30 mL/min </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacokinetic/pharmacodynamic relationship(s) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a randomized, dose-ranging trial, HIV-1&#x2013;infected subjects treated with dolutegravir monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(ING111521) demonstrated rapid and dose-dependent antiviral activity, with mean decline in HIV-1 RNA of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2.5 log</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">10</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> at day 11 for 50 mg dose. This antiviral response was maintained for 3 to 4 days after the last dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the 50 mg group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special patient populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Children </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The pharmacokinetics of dolutegravir in 10 antiretroviral treatment-experienced HIV-1 infected adolescents </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(12 to 17 years) showed that dolutegravir 50 mg once daily dosage resulted in dolutegravir exposure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:758pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">comparable to that</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:12pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed in adults who received dolutegravir 50 mg once daily.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:771pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Limited data are available in adolescents receiving a daily dose of 300 mg of lamivudine. Pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">parameters are comparable to those reported in adults. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Population pharmacokinetic analysis of dolutegravir using data in HIV-1 infected adults showed that there </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was no clinically relevant effect of age on dolutegravir exposure. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacokinetic data for dolutegravir and lamivudine in subjects &gt;65 years of age are limited. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacokinetic data have been obtained for dolutegravir and lamivudine separately.</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal clearance of unchanged active substance is a minor pathway of elimination for dolutegravir. A study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of the pharmacokinetics of dolutegravir was performed in subjects with severe renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(CLcr &lt;30 mL/min). No clinically important pharmacokinetic differences between subjects with severe renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impairment (CLcr &lt;30 mL/min) and matching healthy subjects were observed. Dolutegravir has not been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studied in patients on dialysis, though differences in exposure are not expected. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies with lamivudine show that plasma concentrations (AUC) are increased in patients with renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dysfunction due to decreased clearance.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on the lamivudine data, Dovato is not recommended for patients with creatinine clearance of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt; 30 mL/min. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacokinetic data has been obtained for dolutegravir and lamivudine separately. </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir is primarily metabolized and eliminated by the liver. A single dose of 50 mg of dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was administered to 8 subjects with moderate hepatic impairment (Child-Pugh class B) and to 8 matched </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">healthy adult controls. While the total dolutegravir concentration in plasma was similar, a 1.5 to 2 fold </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increase in unbound exposure to dolutegravir was observed in subjects with moderate hepatic impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to healthy controls. No dosage adjustment is considered necessary for patients with mild to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">moderate hepatic impairment. The effect of severe hepatic impairment on the pharmacokinetics of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir has not been studied. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data obtained in patients with moderate to severe hepatic impairment show that lamivudine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacokinetics are not significantly affected by hepatic dysfunction. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Polymorphisms in drug metabolising enzymes </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no evidence that common polymorphisms in drug metabolising enzymes alter dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacokinetics to a clinically meaningful extent. In a meta-analysis using pharmacogenomics samples </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">collected in clinical studies in healthy subjects, subjects with UGT1A1 (n=7) genotypes conferring poor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects with genotypes associated with normal metabolism via UGT1A1 (n=41). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Gender </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Population PK analyses using pooled pharmacokinetic data from clinical studies where dolutegravir or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lamivudine was administered to adults in combination with other ARVs revealed no clinically relevant effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of gender on the exposure of dolutegravir or lamivudine. There is no evidence that a dose adjustment of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir or lamivudine would be required based on the effects of gender on PK parameters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Race  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Population PK analyses using pooled pharmacokinetic data from clinical studies where dolutegravir was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administered to adults in combination with other ARVs revealed no clinically relevant effect of race on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exposure of dolutegravir. The pharmacokinetics of dolutegravir following single dose oral administration to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Japanese subjects appear similar to observed parameters in Western (US) subjects. There is no evidence that </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">25 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a dose adjustment of dolutegravir or lamivudine would be required based on the effects of race on PK </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">parameters.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Co-infection with Hepatitis B or C  </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Population pharmacokinetic analysis indicated that hepatitis C virus co-infection had no clinically relevant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect on the exposure to dolutegravir. There are limited pharmacokinetic data on subjects with hepatitis B </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">co-infection (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are no data available on the effects of the combination of dolutegravir and lamivudine in animals. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Carcinogenesis and mutagenesis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dolutegravir was not mutagenic or clastogenic using </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> tests in bacteria and cultured mammalian cells, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and an </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in viv</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">o rodent micronucleus assay. Lamivudine was not mutagenic in bacterial tests, but consistent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with other nucleoside analogues, inhibits cellular DNA replication in </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> mammalian tests such as the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mouse lymphoma assay. The results from two in vivo rat micronucleus tests with lamivudine were negative. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine has not shown any genotoxic activity in the </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">in vivo</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> studies.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The carcinogenic potential of a combination of dolutegravir and lamivudine has not been tested. Dolutegravir </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was not carcinogenic in long term studies in the mouse and rat. In long-term oral carcinogenicity studies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rats and mice, lamivudine did not show any carcinogenic potential.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reproductive toxicology studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In reproductive toxicity studies in animals, dolutegravir and lamivudine were shown to cross the placenta. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Oral administration of dolutegravir to pregnant rats at doses up to 1000 mg/kg daily from days 6 to 17 of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">gestation did not elicit maternal toxicity, developmental toxicity or teratogenicity (37.2 times the 50 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">human clinical exposure, based on AUC following single dose in the fasted state). Oral administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir to pregnant rabbits at doses up to 1000 mg/kg daily from days 6 to 18 of gestation did not elicit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">developmental toxicity or teratogenicity (0.55 times the 50 mg human clinical exposure, based on AUC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">following single dose in the fasted state). In rabbits, maternal toxicity (decreased food consumption, scant/no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">faeces/urine, suppressed body weight gain) was observed at 1000 mg/kg (0.55 times the 50 mg human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical exposure, based on AUC following single dose in the fasted state). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lamivudine was not teratogenic in animal studies but there were indications of an increase in early </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">embryonic deaths in rabbits at relatively low systemic exposures, comparable to those achieved in humans. A </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">similar effect was not seen in rats even at very high systemic exposure. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility studies in rats have shown that dolutegravir or lamivudine have no effect on male or female fertility. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Repeated dose toxicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The effect of prolonged daily treatment with high doses of dolutegravir has been evaluated in repeat oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose toxicity studies in rats (up to 26 weeks) and in monkeys (up to 38 weeks). The primary effect of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dolutegravir was gastrointestinal intolerance or irritation in rats and monkeys at doses that produce systemic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">exposures approximately 28.5 and 1.1 times the 50 mg human clinical exposure following single dose in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fasted state based on AUC, respectively. Because gastrointestinal (GI) intolerance is considered to be due to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">local active substance administration, mg/kg or mg/m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> metrics are appropriate determinates of safety cover </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for this toxicity. GI intolerance in monkeys occurred at 30 times the human mg/kg equivalent dose (based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:732pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">50 kg human), and 11 times the human mg/m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> equivalent dose for a total daily clinical dose of 50 mg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:746pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">26 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tablet core </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Microcrystalline cellulose  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sodium starch glycolate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium Stearate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mannitol (E421) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Povidone (K29/32) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sodium stearyl fumarate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tablet coating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypromellose (E464) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Macrogol </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Titanium dioxide (E171) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This medicinal product does not require any special storage conditions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:459pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Opaque, white HDPE (high density polyethylene) bottles closed with child resistant polypropylene closures, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with a polyethylene faced induction heat seal liner. Each pack consists of one bottle containing 30 film-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">coated tablets. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Multipacks containing 90 (3 packs of 30) film-coated tablets. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ViiV Healthcare BV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Van Asch van Wijckstraat 55H </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3811 LP Amersfoort </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Netherlands </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER(S)  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:733pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:745pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/19/1370/001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:759pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/19/1370/002 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:772pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:795pt;left:290pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">27 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorization: 1st July 2019 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:56pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:84pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:56pt"><span style="font-family:Verdana,sans-serif;font-size:9pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:56pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:200pt"><span style="font-family:Verdana,sans-serif;font-size:9pt"> </span></p>
</div>























</body>
</html> 

